Last reviewed · How we verify
Metolazone Tablets
Metolazone Tablets is a Thiazide-like diuretic Small molecule drug developed by NHS Greater Glasgow and Clyde. It is currently FDA-approved for Hypertension, Edema associated with congestive heart failure, Edema associated with renal disease. Also known as: metolazone.
Metolazone inhibits sodium and chloride reabsorption in the distal convoluted tubule of the nephron, promoting urinary excretion of water and electrolytes.
Metolazone is a thiazide-like diuretic that inhibits sodium and chloride reabsorption in the distal convoluted tubule of the nephron, promoting urinary excretion of water and electrolytes to reduce blood volume and blood pressure. Used for Hypertension, Edema associated with congestive heart failure, Edema associated with renal disease.
At a glance
| Generic name | Metolazone Tablets |
|---|---|
| Also known as | metolazone |
| Sponsor | NHS Greater Glasgow and Clyde |
| Drug class | Thiazide-like diuretic |
| Target | Na-Cl cotransporter (NCC) |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Metolazone is a thiazide-like diuretic that blocks the Na-Cl cotransporter in the distal convoluted tubule, reducing blood volume and lowering blood pressure. It also has a mild direct vasodilatory effect on vascular smooth muscle. This dual action makes it effective for hypertension and edema management, particularly in patients with reduced renal function where other diuretics may be less effective.
Approved indications
- Hypertension
- Edema associated with congestive heart failure
- Edema associated with renal disease
Common side effects
- Hypokalemia
- Hyperuricemia
- Hyperglycemia
- Hyponatremia
- Dizziness
- Headache
Key clinical trials
- Optimal Diuretic Therapies for Acute Heart Failure With Volume Overload (PHASE4)
- Fasting Study of Metolazone Tablets 5 mg and Zaroloxyn® Tablets 5 mg (PHASE1)
- Fasting Study of Metolazone Tablets 10 mg and Zaroloxyn® Tablets 10 mg (PHASE1)
- Fasting Study of Metolazone Tablets 2.5 mg and Zaroloxyn® Tablets 2.5 mg (PHASE1)
- Role of Active Deresuscitation After Resuscitation: (PHASE2)
- DAPAgliflozin Versus Thiazide Diuretic in Patients With Heart Failure and Diuretic RESISTance (PHASE3)
- Diuretic Effect of Metolazone Pre-dosing Versus Concurrent Dosing (PHASE4)
- Prospective Comparison of Metolazone Versus Chlorothiazide for Acute Decompensated Heart Failure With Diuretic Resistance (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Metolazone Tablets CI brief — competitive landscape report
- Metolazone Tablets updates RSS · CI watch RSS
- NHS Greater Glasgow and Clyde portfolio CI
Frequently asked questions about Metolazone Tablets
What is Metolazone Tablets?
How does Metolazone Tablets work?
What is Metolazone Tablets used for?
Who makes Metolazone Tablets?
Is Metolazone Tablets also known as anything else?
What drug class is Metolazone Tablets in?
What development phase is Metolazone Tablets in?
What are the side effects of Metolazone Tablets?
What does Metolazone Tablets target?
Related
- Drug class: All Thiazide-like diuretic drugs
- Target: All drugs targeting Na-Cl cotransporter (NCC)
- Manufacturer: NHS Greater Glasgow and Clyde — full pipeline
- Therapeutic area: All drugs in Cardiovascular
- Indication: Drugs for Hypertension
- Indication: Drugs for Edema associated with congestive heart failure
- Indication: Drugs for Edema associated with renal disease
- Also known as: metolazone
- Compare: Metolazone Tablets vs similar drugs
- Pricing: Metolazone Tablets cost, discount & access